MLYS (Mineralys Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by MLYS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-24 | Brian Taylor Slingsby | Director | Sell | — | — |
| 2026-09-22 | Eric Warren | Chief Commercial Officer | MIXED | — | — |
| 2026-09-17 | Daphne Karydas | Director | MIXED | — | — |
| 2026-08-25 | Eric Warren | Chief Commercial Officer | MIXED | — | — |
| 2026-08-12 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-08-12 | James J. Ferguson III | Chief Medical Officer | A | — | — |
| 2026-07-23 | Eric Warren | Chief Commercial Officer | MIXED | — | — |
| 2026-07-20 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-07-15 | Jon Congleton | Chief Executive Officer | Sell | — | — |
| 2026-07-15 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-07-10 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-06-17 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-06-17 | Daphne Karydas | Director | MIXED | — | — |
| 2026-06-12 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-05-19 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-05-13 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-04-21 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-04-15 | Jon Congleton | Chief Executive Officer | Sell | — | — |
| 2026-04-15 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-04-13 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-04-02 | Jon Congleton | Chief Executive Officer | Sell | — | — |
| 2026-04-02 | Daphne Karydas | Director | MIXED | — | — |
| 2026-03-17 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-03-16 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-03-10 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-02-20 | Jon Congleton | Chief Executive Officer | A | — | — |
| 2026-02-20 | GLENN SBLENDORIO | Director | A | — | — |
| 2026-02-20 | David Malcom Rodman | Chief Medical Officer | A | — | — |
| 2026-02-20 | SRINIVAS AKKARAJU | Director | A | — | — |
| 2026-02-20 | Daphne Karydas | Director | A | — | — |
| 2026-02-20 | Adam Scott Levy | CFO and Secretary | A | — | — |
| 2026-02-20 | Derek DiRocco | Director | A | — | — |
| 2026-02-20 | Alexander M Gold | Director | A | — | — |
| 2026-02-20 | RA Capital Nexus Fund III, L.P. | Director | A | — | — |
| 2026-02-20 | Brian Taylor Slingsby | Director | MIXED | — | — |
| 2026-02-17 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-02-13 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-02-11 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-01-20 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-01-15 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-01-13 | Adam Scott Levy | CFO and Secretary | Sell | — | — |
| 2026-01-13 | Jon Congleton | Chief Executive Officer | Sell | — | — |
| 2026-01-13 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2026-01-06 | David Malcom Rodman | Chief Medical Officer | MIXED | — | — |
| 2025-11-24 | Jon Congleton | Chief Executive Officer | M | — | — |
| 2025-11-21 | Brian Taylor Slingsby | Director | Sell | — | — |
| 2025-11-13 | Jon Congleton | Chief Executive Officer | Sell | — | — |
| 2025-11-13 | Alexander M Gold | Director | MIXED | — | — |
| 2025-11-13 | Adam Scott Levy | CFO and Secretary | MIXED | — | — |
| 2025-11-13 | Daphne Karydas | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 7,910,038 | — |
| — | Director | 5,877,218 | — |
| — | 10%+ Owner | 5,674,916 | — |
| — | Director | 5,456,521 | — |
| — | 10%+ Owner | 5,074,916 | — |
| — | 10%+ Owner | 3,218,106 | — |
| — | Director | 1,867,229 | — |
| — | Director | 1,867,229 | — |
| — | Chief Executive Officer | 603,621 | — |
| — | Chief Medical Officer | 102,400 | — |
| — | Chief Medical Officer | 53,554 | — |
| — | CFO and Secretary | 48,538 | — |
| — | Chief Commercial Officer | 38,400 | — |
| — | Director | 9,200 | — |
| — | Director | 6,200 | — |
| — | Director | 6,200 | — |
| — | Director | 6,200 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MLYS quote page; the site-wide leaderboard is on the insider transactions hub.